Abstract:Introduction. Primary hypopharynx involvement of small cell carcinoma is very rare and very few cases have been reported in the literature. Here, we report a case of primary small cell carcinoma of the hypopharynx in a male patient. Case Report. A 50-year-old man presented with a 6-month history of sore throat and swellings in the right side of the neck. Direct laryngoscopy and biopsy revealed small cell carcinoma of the hypopharynx located in the right pyriform sinus.
Discussion. Small cell carcinoma of the … Show more
“…According to previous reports, the average patient age was 64.8 years, ranging from 50 to 78 years (Table 1 ). [ 6 – 10 ] In the previous cases shown in Table 1 , 4 patients were male and 1 patient was female. Four patients had a history of smoking, but no patients had a history of malignancies.…”
Section: Discussionmentioning
confidence: 99%
“…In particular, 3 patients had radiation therapy in adjunction to cisplatin-based chemotherapy. [ 6 , 7 , 10 ] Review of these 3 cases showed that 2 patients were male and that all patients had history of heavy smoking. In 2 cases, the primary tumor was found in the right pyriform sinus.…”
Section: Discussionmentioning
confidence: 99%
“…Previous reports have introduced various therapeutic modalities such as chemotherapy and radiation for SCC of the pyriform sinus, but information regarding optimal treatment remains elusive. [ 6 – 10 ]…”
Background:Primary small cell carcinomas (SCCs) are uncommon in extrapulmonary sites and account for only 2.5% to 5.0% of all SCCs. SCCs in the pyriform sinus are rare and there is little information regarding this disease, especially on therapeutics. Herein, we present a case of successfully treated SCC in the right pyriform sinus that occurred in a patient with small cell lung carcinoma (SCLC) that completely resolved 4 years prior.Methods:A 1.5 × 1.5-cm mass in the right pyriform sinus was detected on imaging studies in a 71-year-old male at a regular check-up visit after being in remission from SCLC.Results:Based on histologic examination and immunohistochemistry, the tumor in the right pyriform sinus was diagnosed as an extrapulmonary SCC. Chemo-radiotherapy was applied to the SCC of the pyriform sinus with a regimen of etoposide and cisplatin. The patient exhibited complete response to treatment and has been disease free for 11 months.Conclusion:This interesting case shows that chemotherapy with concurrent radiation may be an effective therapeutic modality for localized extrapulmonary SCC similar to localized SCLC, which is treated with concurrent chemo-radiotherapy as the standard therapeutic option.
“…According to previous reports, the average patient age was 64.8 years, ranging from 50 to 78 years (Table 1 ). [ 6 – 10 ] In the previous cases shown in Table 1 , 4 patients were male and 1 patient was female. Four patients had a history of smoking, but no patients had a history of malignancies.…”
Section: Discussionmentioning
confidence: 99%
“…In particular, 3 patients had radiation therapy in adjunction to cisplatin-based chemotherapy. [ 6 , 7 , 10 ] Review of these 3 cases showed that 2 patients were male and that all patients had history of heavy smoking. In 2 cases, the primary tumor was found in the right pyriform sinus.…”
Section: Discussionmentioning
confidence: 99%
“…Previous reports have introduced various therapeutic modalities such as chemotherapy and radiation for SCC of the pyriform sinus, but information regarding optimal treatment remains elusive. [ 6 – 10 ]…”
Background:Primary small cell carcinomas (SCCs) are uncommon in extrapulmonary sites and account for only 2.5% to 5.0% of all SCCs. SCCs in the pyriform sinus are rare and there is little information regarding this disease, especially on therapeutics. Herein, we present a case of successfully treated SCC in the right pyriform sinus that occurred in a patient with small cell lung carcinoma (SCLC) that completely resolved 4 years prior.Methods:A 1.5 × 1.5-cm mass in the right pyriform sinus was detected on imaging studies in a 71-year-old male at a regular check-up visit after being in remission from SCLC.Results:Based on histologic examination and immunohistochemistry, the tumor in the right pyriform sinus was diagnosed as an extrapulmonary SCC. Chemo-radiotherapy was applied to the SCC of the pyriform sinus with a regimen of etoposide and cisplatin. The patient exhibited complete response to treatment and has been disease free for 11 months.Conclusion:This interesting case shows that chemotherapy with concurrent radiation may be an effective therapeutic modality for localized extrapulmonary SCC similar to localized SCLC, which is treated with concurrent chemo-radiotherapy as the standard therapeutic option.
“…Conversely, current literature includes only a limited number of pure hypopharyngeal NECs. 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 Table 1 summarises their main characteristics.…”
Section: Discussionmentioning
confidence: 99%
“…Takagawa et al 15 presented a patient who received neck dissection and multiple courses of CRT to the primary and to lung and bone metastases, who deceased 39 months after surgery. Bayram's patient 22 had lung metastases at presentation but responded well to CRT, reported disease‐free 15 months after. Sano et al 14 achieved ‘complete response’ at primary site to CRT in a case of primary small cell carcinoma of the hypopharynx, however the patient died of lung and liver metastases 1 month after treatment.…”
Background
Primary neuroendocrine carcinomas (NECs) are very rare entities accounting for 0.49% of all malignancies. Within the head and neck, the most common sites are the larynx and paranasal sinuses, while the hypopharynx is seldom described.
Case
We present a patient with a poorly differentiated metastatic NEC of the hypopharynx treated palliatively with organ‐preserving surgery and post‐operative chemotherapy, and literature review for well‐documented pure hypopharyngeal NECs. Our patient died of chest infection during chemotherapy, 4 months after surgery.
Conclusion
Chemotherapy remains the mainstay of treatment in the presence of metastases with 2‐year overall survival of 15.7%. Due to the aggressive nature of poorly differentiated metastatic NECs, surgical management is seldom considered. We report and advocate the successful palliative role of organ‐preserving, minimally invasive trans‐oral LASER micro‐surgery and neck dissection to control loco‐regional head and neck disease, safe‐guarding better quality of home life, despite limited life expectancy for this condition.
Objective Two patients with primary small cell carcinoma (SmCC) of the hypopharynx, an extremely rare site for the occurrence of SmCC, are reported and nine additional well-documented cases are reviewed. Methods Case report and review of the literature concerning primary SmCC of the hypopharynx. Results On the final analysis, we reviewed eleven cases of primary SmCC of the hypopharynx. The tumors contained mixed elements of SmCC and squamous cell carcinoma (SCC) in six (55%) of eleven patients. Out of eleven patients, two patients had distant metastasis at the initial presentation. Even though nine patients presented with locoregional disease, development of distant metastasis after treatment was seen in five patients (56%), whereas there was no report of treatment failure on the primary site. To achieve more than two-year survival, patients should have received more than 4 cycles of chemotherapy. Conclusion We report two cases of primary SmCC of the hypopharynx with a review of the literature. In more than half of the cases, combined carcinomas with SCC are seen. Because this tumor has a strong propensity for distant metastasis even in patients with clinically localized tumor, new powerful systemic agents should be explored.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.